Special aspects of the treatment of HIV-2-infected patients

Intervirology

Volumn 55, Issue 2, 2012, Pages 179-183

  Camacho, Ricardo Jorge ^a,b  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b Centro Hospitalar de Lisboa Ocidental   (Portugal)

Author keywords

AIDS; HIV 2 drug resistance; HIV 2 treatment management

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NUCLEOSIDE; RALTEGRAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG MONITORING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IC 50; NONHUMAN; PRIORITY JOURNAL; SALVAGE THERAPY; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

AFRICA, WESTERN; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG MONITORING; DRUG RESISTANCE, VIRAL; GUIDELINES AS TOPIC; HIV INFECTIONS; HIV-2; HUMANS; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84856414956     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000332025     Document Type: Article

References (32)

1. Clavel F, Mansinho K, Chamaret S, Guetard D, Favier V, Nina J, Santos-Ferreira MO, Champalimaud JL, Montagnier L: Human immunodeficiency virus type 2 infection associated with AI-graveS in West Africa. N Engl J Med 1987;316:1180-1185.
2. UNAI-graveS/WHO: AI-graveS epidemic update. Joint United Nations Programme on HIV/AI-graveS (UNAI-graveS), Geneva, 2006.
3. Schim van der Loeff MF, Aaby P: Towards a better understanding of the epidemiology of HIV-2. AI-graveS 1999;13(suppl A): S69-S84.
4. Poulsen AG, Aaby P, Gottschau A, Kvinesdal BB, Dias F, Molbak K, Lauritzen E: HIV-2 infection in Bissau, West Africa, 1987-1989: incidence, prevalence, and routes of transmission. J Acquir Immune Defic Syndr 1993;6:941-948.
5. de Silva TI, Cotten M, Rowland-Jones SL: HIV-2: the forgotten AI-graveS virus. Trends Microbiol 2008;16:588-595.
6. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, De Luca A, Palmisano L, Paraskevis D, Paredes R, Poljack M, Schmidt JC, Soriano V, Walter H, Sönnerborg A: European recommendations for the clinical use of HIV drug resistance testing:2011 update. AI-graveS Rev 2011;13:77-108.
7. Gilleece Y, Breuer J, Hawkins D, Smit E, McCrae LX, Chadwick D, Pillat D, Anderson J, Smith N: The British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals. HIV Med 2010;11:611-619.
8. Almeida G, Arroz MJ, Palma AC, Cabanas J, Abecasis AB, Carvalho AP, Gonçalves MF, Diogo I, Lobo MC, Mansinho K, Camacho RJ, Gomes P: Correlation of plasma viral load with C-grave4+ T cell count on 411 HIV-2-infected patients (abstract PE 6.11/4). 10th European AI-graveS Conference/EACS, Dublin, 2005.
9. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, Pueyo S, Brun-Vezinet F, Chene G, ANRS CO5 HIV-2 Cohort Study Group: C-grave4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 Cohort. AI-graveS 2006;20:459-462.
10. Gustchina A, Weber IT: Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 1991;10:325-339.
11. Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M: Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 1987;326:662-669.
12. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, Campa P, Chene G, Brun-Vezinet F, Descamps D: HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008;62:914-920.
13. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W: Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004;9:57-65.
14. Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA: Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 2007;51:604-610.
15. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Benard A, Campa P, Matheron S, Chene G, Brun-Vezinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 04 VIH-2): In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008;52:1545-1548.
16. Brower ET, Bacha UM, Kawasaki Y, Freire E: Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des 2008;71:298-305.
17. Smith R, Ba S, Hawes S, Toure M, Raugi D, Kim M, Mullins J, Kiviat N, Sow PS, Gottlieb G, UW-Dakar HIV-2 Study Group: Toward optimal ART for HIV-2 infection: Can genotypic and phenotypic drug resistance testing help guide therapy for HIV-2? (abstract 579). 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, 2010.
18. Pieniazek D, Rayfield M, Hu DJ, Nkengasomg JN, Soriano V, Heneine W, Zeh C, Agwale SM, Wambebe C, Odama L, Wiktor SZ, Kalish ML: HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AI-graveS 2004;18:495-502.
19. Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S, ANRS CO5 HIV-2 Cohort Study Group: Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AI-graveS 2009;23:1171-1173.
20. Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston B-grave: Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob Agents Chemother 2008;52:329-332.
21. Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, Pueyo S, Chêne G, Brun-Vezinet F, French ANRS HIV-2 Cohort Study Group: High frequency of selection of K65R and Q151M mutations in patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004;74:197-201.
22. Damond F, Collin G, Matheron S, Peytavin G, Campa P, Taieb A, Bénard A, Chêne G, Brun-Vezinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 5 VIH-2): In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene. Antivir Ther 2005;10:861-865.
23. Cavaco-Silva J, Theys K, Goncalves MF, Neves I, Vera J, Dinis A, Fonseca P, Tavares L, Faria N, Van Laethem K, Vandamme A-M, Gomes P, Mansinho K, Camacho RJ, Portuguese HIV-2 resistance study group: Bayesian network analysis of resistance pathways in HIV-2 reverse transcriptase (abstract 46). 8th European HIV Drug Resistance Workshop (oral presentation), Sorrento, 2010.
24. Cavaco-Silva J, Miranda AC, Gonçalves MF, Valadas E, Mansinho K, Van Laethem M, Vandamme A-M, Gomes P, Camacho RJ, HIV-2 Resistance Study Group: Emergence of K65R in HIV-2-infected patients under therapy. 7th European Drug Resistance Workshop (oral presentation), Stockholm, 2009.
25. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2): HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrobial Chemother 2008;62:914-920.
26. Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S: Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AI-graveS 2008;22:665-666.
27. Bercoff DP, Trinqueneaux P, Lambert C, Oumar AA, Temes A-M, Dao S, Goubau P, Schmit J-C, Ruelle J: Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 2010;7:98.
28. Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2): In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AI-graveS 2010;24:2753-2755.
29. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, Thorstensson R, Fenyo EM, Bjorling E: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999;73:2343-2349.
30. Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult M, Gyllensten K, Moberg L, Brostrom C, Fenyo EM, Albert J: Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 2005;86:3385-3396.
31. Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns B, Pillay D, Nelson M: Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 2010;86:224-226.
32. Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vezinet F, Descamps D, ANRS CO 05 HIV-2 Cohort: Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool (poster 671). Conference on Retroviruses and Opportunistic Infections (CROI), Boston, 2011.